ArticleOpen (repository)2026
Advanced Health Science and Technology Journal · vol. 2 (1) · 104-108
Abstract Objective: This study examined how patient volume and crowding in pediatric emergency departments (EDs) affect the quality of care, focusing on impacts on patients, healthcare staff, and the healthcare system. Methods: A cross-sectional design was used, and data were collected through a structured questionnaire from 134 randomly selected healthcare providers working in pediatric EDs across Riyadh. Descriptive and inferential statistics were applied for data analysis. Results: Pediatric ED crowding significantly affected patients ( M = 4.26, standard deviation [SD] = 0.58, P = 0.001), resulting in lower satisfaction, delayed assessment and treatment, longer hospital stays, and increased mortality risk. Staff outcomes were similarly impacted ( M = 4.29, SD = 0.61, P = 0.001), including higher stress, increased exposure to workplace violence, and slower patient response times. System-level effects were also significant ( M = 4.27, SD = 0.55, P = 0.001), with prolonged ED stays, reduced efficiency, and increased operational costs. Conclusion: Crowding in pediatric EDs has a measurable negative impact on patient safety, staff well-being, and healthcare system performance. These findings highlight the need for evidence-based strategies to improve patient flow, optimize staffing models, and strengthen the efficiency and quality of pediatric emergency care in Riyadh.
patient volumequality of carepatient satisfactionpatient mortality
ReviewOpen access2026
Brain and Spine · vol. 6 · 106164-106164
Introduction: Pediatric idiopathic intracranial hypertension (IIH) and growth plate disorders (GPD) show parallel epidemiological trends and carry possible pathophysiological links, especially regarding obesity and hormonal dysregulation. This study investigated their indirect relationship through structural equation modeling (SEM) to identify age-dependent mechanisms and guide precision treatment strategies. Methods: Following PRISMA 2020 guidelines, we searched literature databases from inception to May 15, 2025, identifying studies reporting pediatric IIH and/or GPD parameters. SEM analysis was performed with age-stratified models to evaluate the mediating effects of obesity and hormonal factors between prepubertal (<10-12 years) and postpubertal (>10-12 years) cohorts. Results: We included 22 eligible studies with total of 2293 individuals. SEM revealed peculiar age-dependent mechanisms. In prepubertal children, venous pressure (β = 0.68, P-value<0.001) and vitamin D/hormonal pathways (β = 0.56, P-value<0.001) dominated, with obesity showing minimal effect (β = 0.28, P-value = 0.001). In a controverse manner, in postpubertal patients, the obesity pathway predominated (β = 0.76, P-value<0.001) with reduced venous (β = 0.29, P-value = 0.003) and hormonal (β = 0.16, P-value = 0.038) contributions. Mechanism-specific therapeutic efficacy showed parallel patterns: acetazolamide/surgical interventions were superior for venous-dominant cases (g = 1.86/1.74), while weight management demonstrated greatest efficacy for obesity-dominant phenotypes (g = 1.75). Vitamin D supplementation showed significant benefit only in hormonal-dominant cases (g = 1.64). Conclusions: Pediatric IIH demonstrates fundamental mechanistic heterogeneity across development. A puberty-associated shift from venous/hormonal to obesity-dominant mechanisms explains the changing demographics and provides a framework for precision treatment. Targeted therapeutic approaches based on dominant mechanisms showed 63% improved outcomes compared to standard of care of IIH.
pediatric idiopathic intracranial hypertensiongrowth plate disordersobesitypuberty
RetractionOpen access2026
RSC Advances · vol. 16 (37) · 40984-40984
Retraction of “Construction of a binary S-scheme S-g-C 3 N 4 /Co-ZF heterojunction with enhanced spatial charge separation for sunlight-driven photocatalytic performance” by Ali Bahadur et al. , RSC Adv. , 2022, 12 , 23263–23273, https://doi.org/10.1039/D1RA08525E.
S-scheme heterojunctiongraphitic carbon nitridecobalt-zinc ferritespatial charge separation
ArticleOpen access2026
Journal of Disability Research · vol. 5 (3)
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide. Public knowledge and awareness of AD play an important role in early recognition, risk reduction, and support for affected individuals. This study aimed to assess AD-related knowledge among adults in Riyadh, Saudi Arabia, using the validated Alzheimer’s Disease Knowledge Scale (ADKS), and to identify sociodemographic factors associated with knowledge levels. A community-based cross-sectional study was conducted among 1282 adults recruited from public locations across Riyadh using a stratified convenience sampling approach. Data were collected through face-to-face interviews using a structured questionnaire and the 30-item ADKS. The scale assessed knowledge across seven domains: life impact, risk factors, disease course, assessment and diagnosis, caregiving, treatment and management, and symptoms. Descriptive statistics, independent-samples t -tests, one-way analysis of variance, Tukey’s post hoc analysis, and multiple linear regression were performed using SPSS version 25 (IBM Corp., Armonk, NY, USA). The mean total ADKS score was 17.09 ± 3.00 out of 30, corresponding to 56.95% correct responses, indicating moderate knowledge of AD among participants. The highest domain-specific knowledge scores were observed in assessment and diagnosis (66.25%) and treatment and management (66.25%), while the lowest scores were observed in caregiving (46.2%). Mean ADKS scores differed significantly by age group ( P = 0.037), gender ( P < 0.001), educational level ( P = 0.007), marital status ( P = 0.007), and family history of AD ( P < 0.001). Multiple linear regression analysis showed that female gender ( B = 0.952, P < 0.001), higher educational level ( B = 0.177, P = 0.012), increasing age category ( B = 0.229, P = 0.012), and having a family history of AD ( B = 0.800, P < 0.001) were independently associated with higher ADKS scores. Adults in Riyadh demonstrated moderate knowledge regarding AD, with notable knowledge gaps particularly related to caregiving and other disease-related domains. Sociodemographic characteristics, especially gender, education, age, and family exposure to AD, were associated with knowledge levels. Targeted community-based educational interventions addressing identified knowledge gaps are warranted to improve AD awareness and promote early recognition and supportive care in Saudi Arabia.
Alzheimer's diseasepublic knowledgehealth awarenessAlzheimer's Disease Knowledge Scale
ReviewOpen access2026
Analytical Cellular Pathology · vol. 2026 (1) · e9281281-e9281281
BACKGROUND: Whole-slide imaging (WSI) has shifted pathology toward digital workflows, creating the foundation for applying artificial intelligence (AI) to diagnostic tasks. This review summarises validated AI applications in diagnostic pathology, with an emphasis on clinical performance, regulatory developments and the practical barriers that affect implementation. METHODS: A structured search of PubMed, Scopus and Google Scholar identified English-language, peer-reviewed studies from January 2020 to May 2025. Eligible studies applied AI to diagnostic, grading or prognostic tasks in human tissue, used a pathologist-confirmed reference standard and included external or multi-centre validation. RESULTS: More than 150,000 digital slides were represented across the included studies. Reported performance metrics demonstrated strong diagnostic accuracy across several validated applications. Large meta-analyses and externally validated studies reported sensitivity values exceeding 96% and specificity above 93% for selected cancer-detection tasks, while other studies demonstrated high agreement for Gleason grading (QWK up to 0.862) and biomarker quantification (Ki-67 ICC 0.98). CONCLUSION: AI has the capacity to strengthen diagnostic pathology by improving consistency, measurement and efficiency. Moving from experimental use to routine reporting will require broad validation across centres, enhanced model transparency, strong quality-assurance systems and close cooperation between developers and pathologists.
artificial intelligencewhole slide imagingdigital pathologyAI implementation barriers
EditorialOpen (repository)2026
Elsevier eBooks · xxiii-xxiv
Book chapterClosed2026
Elsevier eBooks · 175-186
over-the-counter drugsdigitalization of healthcareonline pharmaciestelepharmacy
PreprintOpen (repository)2026
SSRN Electronic Journal
structural dynamicsRhoAUDPconformational change
ArticleOpen access2026
JMA Journal · vol. 9 (5) · 1397-1405
Background: Plaque psoriasis, which is a chronic immune-mediated inflammatory skin condition, significantly reduces patients' quality of life. The cytokine interleukin-23 (IL-23) is a pivotal factor in the development of psoriasis, and icotrokinra is a new oral IL-23 receptor antagonist that has shown potential effectiveness in clinical trials. The main goal of this systematic review and meta-analysis was to assess the effectiveness and safety of icotrokinra in adults and adolescents with moderate-to-severe plaque-type psoriasis. Methods: A comprehensive literature search in PubMed, ScienceDirect, and the Cochrane Library, conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards, identified randomized controlled trials that evaluated daily oral icotrokinra 200 mg versus placebo. The primary outcomes were Psoriasis Area and Severity Index (PASI) 90, Investigator's Global Assessment (IGA) 0/1, and adverse events (AEs) at 16 weeks. Risk ratios with 95% confidence intervals were summed up through a random-effects model. Results: A total of five randomized controlled trials involving 2,755 participants were included. Icotrokinra showed a significant increase in PASI 90, IGA 0/1, IGA 0, and Psoriasis Symptoms and Signs Diary 0 responses compared to placebo. The overall frequency of AEs was similar in both groups, but the rate of treatment discontinuation due to AEs was lower with icotrokinra. Conclusions: Icotrokinra is an effective and well-tolerated oral treatment for moderate-to-severe plaque psoriasis with considerable clinical and patient-reported benefits.
IL-23 inhibitorsplaque psoriasismoderate-to-severe psoriasisefficacy
ArticleOpen access2026
RSC Advances · vol. 16 (44) · 56258-56284
Hepatorenal toxicity stems from chronic oxidative stress (OS) generated from mechanisms underlying chemical or metabolic injury.
berberinehepatoprotectionrenal protectioncarbon tetrachloride
ReviewOpen (repository)2026
Annals of Middle Eastern Medicine
Icotrokinra (JNJ-2113) is a first-in-class targeted oral peptide that selectively binds to the interleukin-23 (IL-23) receptor and blocks IL-23 signaling. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) of Icotrokinra to assess its efficacy and safety versus control in moderate-to-severe plaque psoriasis. We performed a PRISMA-adherent systematic literature search across Scopus, PubMed, and Web of Science from their inception up to January 2026. Screening, data extraction, and risk of bias assessment were made by two independent authors. A meta-analysis was conducted in R with sensitivity and subgroup analyses. We included four studies comprising five RCTs. Oral icotrokinra significantly improved physician-assessed and psoriasis area and severity index (PASI) responses compared with control in RCTs. For Investigator’s Global Assessment (IGA) 0/1, benefit was evident by week 2 (risk ratios (RR) = 3.24%, 95% confidence interval (CI) 1.01–10.46) and remained consistent through week 16 (RR = 7.35%, 95% CI 5.67–9.54), with an overall pooled effect RR = 7.31 (95% CI 6.25–8.55). Complete clearance (IGA 0) emerged from week 8 (RR = 23.65%, 95% CI 6.74–82.95), overall RR = 12.44 (95% CI 6.88–22.51). PASI 75 overall RR = 6.74 (95% CI 5.75–7.91); PASI 90 RR = 14.38; PASI 100 RR = 11.17. PSSD symptom 0 at week 16: 256/1226 vs 9/551 (RR=9.62%, 95% CI 5.14–18.01). Icotrokinra offers rapid and clinically significant improvements in plaque psoriasis, particularly on IGA and PASI, and these responses continue to improve over time; by week 8, complete clearance became significantly more frequent with icotrokinra. Safety outcomes were comparable between icotrokinra and placebo, and there was no meaningful increase in serious adverse events.
plaque psoriasisIL-23 receptor antagonistPASI responseInvestigator's Global Assessment
ReviewOpen (repository)2026
Annals of Middle Eastern Medicine
The long-term comparative outcomes of on-pump and off-pump coronary artery bypass grafting (CABG) remain disputed. We performed a random-effects meta-analysis of 25 randomized controlled trials (18,729 patients) comparing on-pump versus off-pump CABG, searching MEDLINE/PubMed, Cochrane CENTRAL, Web of Science, ProQuest, ClinicalTrials.gov, Scopus, and grey literature through 7 June 2025. Outcomes (repeat revascularization, late myocardial infarction, stroke/TIA, late mortality, major adverse cardiovascular events [MACE], and composite endpoints) were pooled as hazard ratios (HR) with 95% confidence intervals (CI), expressed as on-pump versus off-pump. On-pump CABG significantly reduced late myocardial infarction (HR 0.58; p = 0.01). Off-pump CABG was associated with significantly lower MACE (HR 1.62; p = 0.003), with the greatest benefit at 5–10 years (HR 2.18; p < 0.00001) and persisting beyond 10 years (HR 1.89; p = 0.03), and with a lower composite-endpoint risk (HR 1.24; p = 0.04). No significant differences were found for late mortality, repeat revascularization, or stroke/TIA. Risk of bias was moderate to high, and the certainty of evidence was low to very low for most outcomes. On-pump CABG confers a long-term reduction in myocardial infarction, whereas off-pump CABG is associated with a lower MACE and composite cardiovascular event burden; neither technique differs for late mortality, repeat revascularization, or cerebrovascular events. Surgical strategy should be individualized, and further high-quality trials are warranted.
on-pump coronary artery bypass graftingoff-pump coronary artery bypasscardiopulmonary bypassmajor adverse cardiovascular events
ReviewOpen (repository)2026
Annals of Middle Eastern Medicine
Background: Relapsing-remitting multiple sclerosis is a chronic immune-mediated disorder of the central nervous system associated with recurrent inflammatory activity and long-term disability accumulation. Although escalation therapy has traditionally been used, early initiation of high-efficacy disease-modifying therapies may provide stronger inflammatory control and improve long-term outcomes. Objective: This systematic review and meta-analysis aimed to compare early initiation of high-efficacy disease-modifying therapies with escalation or delayed treatment strategies in adults with relapsing-remitting multiple sclerosis. Methods: PubMed, Scopus, and Web of Science were systematically searched. Eligible studies included adults with relapsing-remitting multiple sclerosis treated with either early high-efficacy disease-modifying therapies or escalation/delayed strategies. Outcomes included annualized relapse rate, Expanded Disability Status Scale change, and delta-Expanded Disability Status Scale. Study quality was assessed using the Newcastle-Ottawa Scale, and pooled analyses were performed using random-effects models. Results: Ten observational cohort studies were included. Early initiation of high-efficacy treatment was associated with lower annualized relapse rate than escalation therapy. Disability findings remained uncertain. The pooled EDSS-change analysis was not statistically significant and showed considerable heterogeneity. Only one eligible study reported an adjusted delta-EDSS comparison; therefore, this outcome was reported narratively and was not meta-analyzed. Nonrandom treatment allocation and potential confounding by indication limit causal interpretation. Conclusion: Early initiation of high-efficacy disease-modifying therapy was associated with lower relapse activity in observational RRMS cohorts. The available disability evidence does not establish a causal advantage of either treatment strategy and requires cautious interpretation.
relapsing-remitting multiple sclerosisdisease-modifying therapyearly treatment initiationtreatment delay
ReviewOpen (repository)2026
Annals of Middle Eastern Medicine
Background: Chemical peels are widely used for mild-to-moderate acne vulgaris, but comparative evidence is dispersed across small trials and multiple active formulations. This review synthesized the supplied randomized evidence and compared efficacy and tolerability across peel types using network meta-analysis. Methods: PubMed, the Cochrane Library, Scopus, and Web of Science were searched for randomized active-comparator trials of chemical peels for acne vulgaris up to June 2026. Random-effects network meta-analyses used standardized mean differences (SMDs) for continuous outcomes and risk ratios (RRs) for categorical and safety outcomes, each with 95% confidence intervals (CIs). Salicylic acid was the reference treatment, and treatments were ranked using surface under the cumulative ranking curve (SUCRA) values. Results: Twenty-three randomized trials with reported enrollment totaling 1,170 participants were included. Most continuous efficacy comparisons were not statistically significant. Relative to salicylic acid, Jessner's solution was associated with a smaller reduction in papule count (SMD 2.49, 95% CI 1.28 to 3.70) and a smaller reduction in Michaelsson acne score (SMD 1.78, 95% CI 0.41 to 3.16). Salicylic plus mandelic acid ranked highest for good improvement (SUCRA 91.9%), but its RR versus salicylic acid was imprecise (RR 1.96, 95% CI 0.75 to 5.13). Trichloroacetic acid was associated with more erythema than salicylic acid (RR 2.74, 95% CI 1.10 to 6.78). Heterogeneity was substantial for non-inflammatory lesion count, papule count, pustule count, and Michaelsson acne score. Treatment-label fragmentation and undocumented handling of split-face correlations limited confidence in rankings. Conclusion: Our analysis does not establish broad superiority of one chemical peel for acne vulgaris. Salicylic acid performed favorably against Jessner's solution for selected efficacy outcomes and had a lower erythema risk than trichloroacetic acid, but most estimates were imprecise and several networks were heterogeneous. Treatment choice should remain individualized, and the findings require confirmation in rigorously reported head-to-head trials with standardized outcomes.
chemical peelsacnesalicylic acidJessner's solution
ArticleOpen access2026
Journal of Chemical Research
CytotoxicityChemistryIn silicoIn vitro